Clinical Trial Update: A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of oral AMN107 (imatinib) in adults with chronic myeloid leukemia and other hematologic malignancies has completed enrollment with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia Philadelphia Chromosome-positive
• Chronic Myeloid Leukemia
• Hypereosinophilic Syndrome
• Systemic Mastocytosis

Drugs mentioned

• AMN107 (imatinib) (imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-06-29